Fate Therapeutics, Inc. - FATE STOCK NEWS

Fate Therapeutics (NASDAQ: FATE) has announced significant progress in its clinical research with the publication of preclinical study results on TCR^-CAR⁺ iPSC-derived CD8αβ T cells, demonstrating robust anti-tumor responses in systemic leukemia models. These findings support the ongoing Phase 1 study of FT819, a first-of-its-kind iPSC-derived T-cell therapy, aimed at treating relapsed/refractory B-cell malignancies. The research, conducted with Memorial Sloan Kettering Cancer Center, highlights the potential for off-the-shelf cancer immunotherapies that overcome manufacturing challenges associated with traditional therapies.

Fate Therapeutics reported its Q2 2022 results, highlighting ongoing clinical trials for its product candidates targeting aggressive B-cell lymphoma and solid tumors. The company has initiated enrollment in multiple studies, including FT596+R for relapsed/refractory B-cell lymphoma and FT536 for solid tumors. With $580.8 million in cash and $18.5 million in revenue for the quarter, Fate is actively expanding collaborations with Janssen and ONO. R&D expenses totaled $81.3 million, reflecting investment in its innovative therapies.

Fate Therapeutics (NASDAQ: FATE) announced a conference call on August 3, 2022, at 5:00 PM ET to discuss its Q2 2022 financial results and provide a corporate update. The call can be accessed via phone or a live audio webcast available on the Company’s website. Fate Therapeutics focuses on developing advanced cellular immunotherapies for cancer patients, utilizing its proprietary induced pluripotent stem cell (iPSC) technology. The Company aims to establish a leadership position in the clinical development of universal, off-the-shelf cell products.

Fate Therapeutics (NASDAQ: FATE) has appointed Brian T. Powl as Chief Commercial Officer, bringing extensive experience in commercial leadership for hematologic malignancies. Powl previously led the global commercial strategy for CAR T-cell therapies at Celgene. His expertise is expected to enhance Fate's late-stage clinical development and product launch pathways for off-the-shelf cellular immunotherapies. Powl received options for 70,000 shares and 45,000 restricted stock units, both vesting over four years, aligning his incentives with company performance.

Fate Therapeutics (NASDAQ: FATE) expands its collaboration with ONO Pharmaceutical to develop CAR NK and CAR T-cell candidates targeting solid tumors. This enhanced partnership includes ONO contributing novel binding domains for a second solid tumor antigen. Fate will lead preclinical development, with ONO having an option for global commercialization. The deal ensures ongoing research funding for Fate and potential milestone payments, including tiered royalties on net sales. Fate's innovative iPSC product platform supports mass production of engineered cell products for cancer treatments.

Fate Therapeutics (NASDAQ: FATE) will present at the 2022 Jefferies Global Healthcare Conference on June 10, 2022, at 9:00 AM ET in New York. The company focuses on developing programmed cellular immunotherapies for cancer patients, leveraging its proprietary induced pluripotent stem cell (iPSC) platform. A live webcast of the presentation will be available in the Investors section of the company's website, with an archived version accessible shortly after the event.

Fate Therapeutics, a clinical-stage biopharmaceutical company focused on cellular immunotherapies, announced its participation in two upcoming investor conferences. The BofA Securities 2022 Healthcare Conference will be held on May 12, 2022, at 12:20 PM ET in Las Vegas, Nevada. Additionally, the H.C. Wainwright Annual Global Life Sciences Conference will be available on demand starting May 24, 2022, at 7:00 AM ET. Interested investors can access live webcasts of the presentations on the company’s website. Fate Therapeutics aims to develop innovative cell therapies for cancer treatment.

Fate Therapeutics (NASDAQ: FATE) reported significant advancements in Q1 2022, with ongoing patient enrollment in multiple trials for its CAR T-cell therapies aimed at treating relapsed/refractory B-cell lymphoma and acute myeloid leukemia. Notably, FT596's clinical protocol combining it with R-CHOP will be submitted to the FDA in 2Q22. The company holds $641.7 million in cash and investments and recorded $18.4 million in revenue, largely from collaborations. However, R&D expenses totaled $72.1 million, highlighting an ongoing financial commitment to innovation.

Fate Therapeutics, a clinical-stage biopharmaceutical company, will host a conference call on May 4, 2022, at 5:00 PM ET to discuss its first quarter 2022 financial results and provide a corporate update. Participants can join via phone or listen to the live audio webcast available on the company’s website. Fate Therapeutics is focused on developing first-in-class programmed cellular immunotherapies targeting cancer patients, utilizing its proprietary iPSC product platform for creating off-the-shelf NK and T-cell therapies.